Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis

Overview

The aim of this study was to clarify the prognostic value of serum pro-Adrenomedullin level in neonatal sepsis. Eighty term and preterm neonates with sepsis were enrolled in this study. Eighty healthy matched neonates served as a control group.

Full Title of Study: “Zekai Tahir Burak Maternity Teaching Hospital Neonatal Intensive Care Unit”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2011

Arms, Groups and Cohorts

  • Clinical sepsis
  • Proven sepsis
  • Control group
    • healthy neonates

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical sepsis and/or proven sepsis. Exclusion Criteria:

  • Acute kidney injury – Intracranial hemorrhage (Grade III and IV)

Gender Eligibility: All

Minimum Age: 24 Weeks

Maximum Age: 42 Weeks

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Zekai Tahir Burak Women’s Health Research and Education Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mehmet Yekta, Zekai Tahir Burak Maternity and Teaching Hospital – Zekai Tahir Burak Women’s Health Research and Education Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.